TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16621906
Drug: Gonadotropin suppression
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin suppression by GnRH antagonist (cetrorelix) with testosterone and additional administration of the gestogen desogestrel (CTD group)
Study: 16621906
Drug: Gonadotropin suppression
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin suppression by GnRH antagonist (cetrorelix) with testosterone (CT group)
Study: 8640161
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and colony-stimulating factors (group I)
Study: 8640161
Drug: G‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF alone (18 patients)
Study: 26715196
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion (30 ml/kg whole blood)
Study: 26715196
Drug: Conservative transfusion
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative transfusion (20 ml/kg)
Study: 24384959
Drug: ATP‐TCA directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP‐TCA directed chemotherapy regimen (specific regimens include paclitaxel+carboplatin, paclitaxel+oxaliplatin, bleomycin+ifosfamide+cisplatin, bleomycin+vincristine+cisplatin, fluorouracil+cisplatin, gemcitabine+cisplatin)
Study: 24384959
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group chemotherapy regimen confirmed by clinical experience
Study: 20473991
Drug: Soybean plus
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean plus fish oil emulsion (1.0 and 0.2 g per kg per day respectively)
Study: 20473991
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil alone (1.2 g per kg bodyweight per day; control group)
Study: 12610030
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) plus free blood testing strips
Study: 7040158
Drug: Bethanechol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol and antacid
Study: 7040158
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and antacid
Study: 28274246
Drug: TNF‐α production
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α production less than 250 pg/ml after lipopolysaccharide stimulation on day 3
Study: 27208415
Drug: Trehalose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trehalose (100 g/day)
Study: 23032742
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with modified HLA class I tumor peptides (Melan‐A/MART‐1([27L]), gp100([210M]), NY‐ESO‐1([165V]), and Survivin([97M])) emulsified in Montanide ISA51, injected subcutaneously with cyclophosphamide (300 mg/m(2)) and low‐dose IL‐2 (3 × 10(6) IU).
Study: 19541691
Drug: Collagen-gentamicin sponges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-gentamicin sponges applied between sternal halves in addition to routine intravenous antibiotics
Study: 19541691
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous study with intravenous prophylaxis only)
Study: 17641452
Drug: Extra-curricular aerobic
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-curricular aerobic dynamic physical activity (swimming, water games, folk dance, soccer) for 35 weeks, 45 min of physical classes plus three 60 min sessions weekly
Study: 17641452
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (43 overweight or obese boys) with only two curricular physical education classes weekly
Study: 15365965
Drug: Low-dose intraperitoneal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intraperitoneal immunoglobulin (IgG) 2 mL (320 mg) with every exchange
Study: 15365965
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic treatment (2-week IP ampicillin+sulbactam/netilmycin combination)
Study: 11231701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.2 mg/d
Study: 11231701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.4 mg/d
Study: 11231701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.6 mg/d
Study: 11231701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.8 mg/d
Study: 11231701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1.0 mg/d
Study: 8349067
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg/d)
Study: 3768492
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of trimazosin
Study: 3768492
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of trimazosin
Study: 28988765
Drug: UroRCC multi-peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UroRCC multi-peptide vaccine
Study: 30355323
Drug: Autologous adipose
Normalized name: Autologous adipose derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose tissue injection
Study: 23020132
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg) plus trametinib (2 mg)
Study: 19996977
Drug: 10-day oral
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day oral quadruple therapy regimen with omeprazole (20 mg, twice daily), tetracycline (750 mg, three times daily), metronidazole (500 mg, three times daily), and bismuth potassium citrate (300 mg, twice daily)
Study: 18751503
Drug: Clindamycin 75
Normalized name: clindamycin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 75 mg capsule (test 1)
Study: 15701488
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) starting on postoperative day 3
Study: 10619544
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of electric shocks
Study: 1820293
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril t.i.d.
Study: 1820293
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg frusemide or placebo
Study: 31755915
Drug: Pembrolizumab (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (up to 2 doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities)
Study: 25618968
Drug: Danzhixiaoyao pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danzhixiaoyao pill (DZXYP)
Study: 22738907
Drug: Waitlist control/delayed‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control/delayed‐treatment condition
Study: 18395716
Drug: Coenzyme Q(10),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q(10), 200 mg/day
Study: 15293818
Drug: TTO-gel (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTO-gel (2.5 per cent)
Study: 15293818
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) gel (0.2 per cent)
Study: 11165126
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extract treatment (ML-1 standardized mistletoe preparation)
Study: 11165126
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mistletoe treatment)
Study: 7975966
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (3 mg vaginal tablet or 0.5 mg intracervical gel)
Study: 2686737
Drug: Captopril (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (twice or three times daily)
Study: 19404617
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg daily for 7 days)
Study: 19404617
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg acute and 300 mg sub-acute)
Study: 16940077
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin-tazobactam 12 g/1.5 g administered continuously over 24 h
Study: 16940077
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin-tazobactam 3 g/0.375 g administered over 30 min every 6 h for 4 to 14 days
Study: 15620828
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin-tazobactam
Study: 11939682
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin-tazobactam
Study: 16940077
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion and intermittent infusion
Study: 14676594
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet with oral placebo for 5 months
Study: 14676594
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet with oral vitamin E (400 mg/d x 2 months, 100 mg/d x 3 months)
Study: 31356703
Drug: present‐centered therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: present‐centered therapy (PCT; 10 sessions delivered over 8 weeks)
Study: 31356703
Drug: minimal contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: minimal contact control (MCC; weekly therapist phone check‐in for 4 weeks)
Study: 25633475
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (12 or 24 weeks, once or twice per week)
Study: 25633475
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (supervised, twice per week for 24 weeks)
Study: 22647826
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, lansoprazole 30 mg twice daily for 5 days)
Study: 22647826
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin 1000 mg, clarithromycin 500 mg, lansoprazole 30 mg twice daily for 7 days)
Study: 28428322
Drug: Multiple Daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Daily Insulin Injections (MDI)
Study: 15243929
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (ACP)
Study: 15243929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ACP vaccine)
Study: 11181931
Drug: Cocaine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.2 mg/kg i.v.
Study: 11181931
Drug: Cocaine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.4 mg/kg i.v.
Study: 11181931
Drug: Cocaine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (both doses)
Study: 2897558
Drug: Acetylcholine sweatspot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine sweatspot test (0.1 ml 1% acetylcholine administered intradermally)
Study: 30185575
Drug: Unguided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided Internet-based cognitive behaviour therapy (ICBT)
Study: 26522083
Drug: Azacitidine/chemotherapy (arm-A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine/chemotherapy (arm-A)
Study: 26522083
Drug: Chemotherapy (arm-B)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (arm-B)
Study: 16186270
Drug: HIIP 2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIP 2.6 mg
Study: 16186270
Drug: HIIP 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIP 5.2 mg
Study: 16186270
Drug: HIIP 7.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIP 7.8 mg
Study: 27885499
Drug: Doxazosin 8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 8 mg
Study: 9566806
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of buprenorphine (maintenance doses every 24 h)
Study: 9566806
Drug: Alternate-day dosing
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day dosing of buprenorphine (double maintenance doses every 48 h with placebo on intervening days)
Study: 8070504
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of metoprolol (100 mg)
Study: 8070504
Drug: Sustained‐release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained‐release formulation of metoprolol (100 mg)
Study: 3135786
Drug: Praziquantel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (2 x 20 mg kg‐1)
Study: 3135786
Drug: Oltipraz (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz (2 x 15 mg kg‐1)
Study: 12693575
Drug: Mass chemotherapy
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass chemotherapy
Study: 28583342
Drug: Flibanserin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin (100 mg/d)
Study: 21295494
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day for 30 days, then 10 mg/day for 60 days
Study: 21295494
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day to 10 mg/day
Study: 20606776
Drug: HESA-A (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HESA-A (25 mg/Kg twice a day orally for 4 weeks)
Study: 20606776
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same method as treatment for 4 weeks)
Study: 16696414
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen suspension (3 doses given 24 hours apart)
Study: 15208824
Drug: Aprepitant (Emend)
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant (Emend) in combination with standard antiemetic agents
Study: 30978265
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic therapy
Study: 8143470
Drug: 37.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 g/day of albumin until the circulating albumin concentration increased to > 3.0 g/dL (> 30 g/L)
Study: 2646246
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied 2% glycopyrrolate lotion/cream
Study: 31500854
Drug: Sevelamer 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 0.8 g (low-dose)
Study: 31500854
Drug: Sevelamer 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 2.4 g (high-dose)
Study: 31500854
Drug: Sevelamer (high-dose)
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer (high-dose) in highest baseline phosphate quartile group
Study: 23539427
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of bisoprolol fumarate 5 mg and hydrochlorothiazide 6.25 mg
Study: 19697824
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 microg kg(‐1) over 10 min, followed by 0.2 microg kg(‐1) h(‐1) continuous infusion)
Study: 16537185
Drug: Single epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single epirubicin (80 mg/40 mL of normal saline) administered into the bladder within 6 hours postoperation
Study: 16537185
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Epirubicin consecutively, instillation every week for 6-8 weeks and then every one month for 10 months
Study: 16537185
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mitomycin C, consecutively, instillation every week for 6-8 weeks and then every one month for 10 months
Study: 2487539
Drug: tiapamil 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapamil 450 mg b.i.d.
Study: 322529
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of vitamin C
Study: 27056586
Drug: Reslizumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab 3.0 mg/kg
Study: 25974287
Drug: Amitriptyline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (titrated to a median of 50 mg, interquartile range 25-50 mg)
Study: 19234425
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions over 5 weeks)
Study: 16317318
Drug: Visual-feedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual-feedback therapy (bimonthly sessions)
Study: 12725603
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with omeprazole, clarithromycin, and tinidazole for 7 days followed by omeprazole for 21 days
Study: 12725603
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with omeprazole, clarithromycin, and tinidazole for 7 days followed by placebo for 21 days
Study: 8259721
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 200 mg daily and placebo
Study: 8259721
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) and Methotrexate (MTX) 7.5 mg once a week
Study: 3916621
Drug: Computer assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer assisted conventional insulin therapy
Study: 12949925
Drug: Cognitive‐behavior therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavior therapy
Study: 11729513
Drug: TPN +
Normalized name: Total Parenteral Nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN + FDP (1 g/kg daily for dogs; 5 g, two times a day for patients)
Study: 31079530
Drug: Sodium reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium reduction (9 slow sodium tablets daily for 6 weeks)
Study: 31079530
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo tablets daily for 6 weeks)
Study: 26387142
Drug: Trastuzumab/chemotherapy (from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab/chemotherapy (from NOAH trial)
Study: 26387142
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (from NOAH trial)
Study: 21673612
Drug: Plain polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain polysaccharide vaccine (MenC-PS group, n=150)
Study: 21673612
Drug: Glycoconjugate vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoconjugate vaccine (MenC-CRM group, n=95)
Study: 18325740
Drug: Galantamine (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (32 mg/day)
Study: 12628548
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GR-1 and L. fermentum RC-14
Study: 23301548
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)/TDF therapy
Study: 23301548
Drug: TDF or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF or FTC/TDF therapy
Study: 21973194
Drug: 1064-nm Q-switched
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064-nm Q-switched neodymium-doped yttrium-aluminium-garnet laser monotherapy
Study: 15349912
Drug: Telbivudine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 800 mg/d
Study: 15349912
Drug: Telbivudine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (various doses: 25, 50, 100, 200, 400, and 800 mg/d)
Study: 15349912
Drug: Telbivudine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (400 mg/d or more)
Study: 8839087
Drug: Metoclopramide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.25 mg.kg-1 intravenously (two doses)
Study: 8839087
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg.kg-1 intravenously (two doses)
Study: 1495854
Drug: High-frequency jet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency jet ventilation (HFJV) with continued surfactant therapy
Study: 6379678
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg indoprofen 4-times daily
Study: 6379678
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg indomethacin 4-times daily